Hair follicles as immune targets: unraveling cellular players, cytokine crosstalk, and precision pathways for future therapy of alopecia areata.

INTRODUCTION

Alopecia areata (AA) is a relapsing autoimmune disorder caused by the collapse of anagen hair-follicle immune privilege, leading to targeted cytotoxic injury of the hair bulb. Its clinical heterogeneity reflects distinct immune endotypes that shape treatment response.

AREAS COVERED: This narrative review synthesizes recent single-cell, spatial transcriptomic, and immunogenetic studies to define the cellular circuits driving AA and their therapeutic implications. Emerging multi-omics datasets identify three reproducible endotypes-IFN-γ-dominant, IL-17-skewed, and mixed Th1/Th17-each associated with distinct follicular microenvironments. Spatial profiling highlights CXCL10+ peribulbar niches enriched for CD8+ NKG2D+ T cells and dysfunctional follicular-resident Tregs. We summarize evidence from Phase III JAK-inhibitor trials, mechanistic studies of relapse biology, and early-stage platforms including IL-15 blockade, antigen-specific tolerization, and nanoparticle-based delivery systems.

EXPERT OPINION: AA is best understood as an endotype-stratified autoimmune disease in which JAK inhibition provides effective but often temporary control due to persistent tissue-resident memory T-cell circuits. Over the next five years, integration of multi-omics diagnostics with targeted immune reprogramming, particularly Treg-restoring and tolerance-inducing strategies, has the potential to deliver more durable remission.